U.S. Pharmaceuticals & Biotech High ROE Growth Engines

Incyte

Market Cap: US$19.9b

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

Exelixis

Market Cap: US$13.1b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

ACADIA Pharmaceuticals

Market Cap: US$3.6b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Theravance Biopharma

Market Cap: US$860.4m

A biopharmaceutical company, develops and commercializes medicines in the United States.

CorMedix

Market Cap: US$679.4m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Abeona Therapeutics

Market Cap: US$322.0m

A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.

Compugen

Market Cap: US$192.0m

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

Spero Therapeutics

Market Cap: US$160.4m

A clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

Oramed Pharmaceuticals

Market Cap: US$154.3m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Vaxart

Market Cap: US$135.7m

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.